The European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney ...

European biotechs have historically struggled to find capital on the continent, but the funding ecosystem now aims to scale ...

Sweeping changes made by RFK Jr at the CDC have weakened the US's immunisation programme, according to former ACIP members.

Teva Pharmaceutical has announced a collaboration with Fosun Pharma to advance the global development of the ATTENUKINE ...

NextCure has entered a strategic partnership with Simcere Zaiming, to develop SIM0505, a new ADC targeting CDH6 for treating ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Ethris has entered a strategic partnership with Thermo Fisher Scientific for providing completely integrated mRNA solution.

Lynozyfic’s global sales are projected to reach $707 million by 2031.

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.